Predicting Response to PARP Inhibitor Therapy in Ovarian Cancer
Michael Birrer, MD, PhD, professor of medicine in the Division of Hematology-Oncology, and Director of the Comprehensive Cancer Center at the University of Alabama at Birmingham, discusses current data on predicting response to PARP inhibitor therapy in ovarian cancer.
Michael Birrer, MD, PhD, professor of medicine in the Division of Hematology-Oncology, and Director of the Comprehensive Cancer Center at the University of Alabama at Birmingham, discusses current data on predicting response to PARP inhibitor therapy in ovarian cancer.
Birrer says there is a lot of level 1 evidence to show which patients will benefit most from PARP inhibition. It is now known that the patients who will derive the most benefit have germline or somaticBRCA1/2mutations. However, patients who have mutations in other genes within the Fanconi pathway, and possibly patients who have alterations of BRCA1/2 through mechanisms other than mutations, may also benefit from these therapies, Birrer says.
Additionally, patients whose tumors demonstrate a high degree of homologous recombination also benefit from PARP inhibitors, Birrer explains. Still, there are patients who do not demonstrate any of the above and still benefit from PARP inhibition.
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
